Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
08:05pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
Data From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual Meeting and Exposition; Advancing CPI-818 Development for Autoimmune and Allergic Diseases
Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
01:52pm, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT
Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast on December 12, 2022 at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
08:05pm, Thursday, 27'th Oct 2022 GlobeNewswire Inc.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
04:05pm, Thursday, 27'th Oct 2022
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
08:05pm, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
BURLINGAME, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022
02:03pm, Friday, 07'th Oct 2022 Benzinga
Upgrades
For Federal Signal Corp (NYSE:FSS), DA Davidson upgraded the previous rating of Neutral to Buy. In the second quarter, Federal Signal showed an EPS of $0.53, compared to $0.50 from the year-a
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
08:05pm, Monday, 26'th Sep 2022 GlobeNewswire Inc.
Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals Mupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals
Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
08:05pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will p
Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
04:05pm, Tuesday, 06'th Sep 2022
BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will pre
Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus (CRVS) Moves to Buy: Rationale Behind the Upgrade
01:33pm, Thursday, 11'th Aug 2022
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2022 Results - Earnings Call Transcript
08:21pm, Monday, 08'th Aug 2022
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research
08:05pm, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
08:23am, Tuesday, 28'th Jun 2022 Benzinga
Gainers
Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
Acutus Medical, Inc. (NASDAQ: AFIB) climbed 87.6% to cl
